Sumit Chanda - From HIV to Covid-19 (EP.01)
Answering the Call to Action
Sumit Chanda sits down with Daniel Haders II, Ph.D. in Episode 1 of our four-part series discussing his lab’s research in HIV and their pivot to study SARS-CoV-2 (COVID-19) at the beginning of the pandemic. Dr. Chanda discusses how his lab answered the call to action for COVID-19 using an agnostic approach to understand host-pathogen interactions, along with the role of therapeutics in curbing future pandemics.
Model Medicines recently partnered with the Chanda Lab at Sanford Burnham Prebys Medical Discovery Institute to discover and develop new treatments for COVID-19 and other infectious diseases.
Sumit Chanda earned his Ph.D from Stanford University in 2001, and received his post-doctoral training at the Genomics Institute of the Novartis Research Foundation (GNF). He subsequently transitioned to a Group Leader position, and established his research group in the Division of Cellular Genomics at GNF. In 2007, he joined the Infectious and Inflammatory Disease Center at Sanford-Burnham Medical Research Institute as an Associate Professor. Dr. Chanda was promoted to Professor in 2013. In 2015, he was appointed Director of the Immunity and Pathogenesis Program at Sanford Burnham Prebys Medical Discovery Institute.
